Echo Therapeutics (ECTE) Closes 3.2M Offering at 95c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
Echo Therapeutics (ECTE) Underwriters Exercise Full Overallotment in 3.2M Offering
December 26, 2012 4:19 PM ESTEcho Therapeutics, Inc. (Nasdaq: ECTE) announced the full exercise of the over-allotment option granted to the underwriters to purchase 480,000 additional common shares, at a public offering price of $0.95 per share, in connection with its previously announced underwritten public offering of 3,200,000 shares of common stock,... More
Echo Therapeutics (ECTE) Prices 3.2M Offering at 95c/Share
December 21, 2012 7:06 AM ESTEcho Therapeutics, Inc. (Nasdaq: ECTE) today announced the pricing of a previously announced underwritten public offering of 3,200,000 shares of its common stock, offered at a price to the public of $0.95 per share. The gross proceeds to Echo from this offering are expected to be approximately $3.0... More
Echo Therapeutics (ECTE) Announces Common Offering
December 20, 2012 4:26 PM ESTEcho Therapeutics, Inc. (Nasdaq: ECTE) intends to offer for sale its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be... More
